Relationship Between 25(OH)D and IGF-I in Children and Adolescents with Growth Hormone Deficiency

Witkowska–Sędek, Ewelina; Kucharská, Anna; Rumińska, Małgorzata; Pyrżak, Beata

doi:10.1007/5584_2016_212

Cited by 22 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Epidemiological studies have suggested that serum IGF-1 level correlates with fracture risk, bone density and bone mass (Rosen, 2004;Niu et al, 2005;He et al, 2006;Léger et al, 2007;Locatelli et al, 2014;Devesa et al, 2016). Several authors have evaluated the association between the GH/IGF-1 axis and vitamin D status (Gómez et al, 2004;Bogazzi et al, 2011;Ameri et al, 2013;Witkowska-Sędek et al, 2016;Ciresi et al, 2017;Trummer et al, 2017). The study by Ameri et al (2013) showed that vitamin D could increase circulating IGF-1 level in adults and better vitamin D status may facilitate the achievement of normal IGF-1 values in GHD.…”

Section: Discussionmentioning

confidence: 99%

“…The effects of the GH/IGF-1 axis on bone turnover can be evaluated using the measurement of bone turnover markers (BTMs), including ALP and BALP (Ono et al, 1996;Locatelli et al, 2014;Devesa et al, 2016). The GH/IGF-1 axis can modulate vitamin D metabolism and, conversely, vitamin D can influence IGF-1 concentrations (Soliman et al, 2008;Bogazzi et al, 2011;Ameri et al, 2013;Ciresi et al, 2014;Witkowska-Sędek et al, 2016;Ciresi et al, 2017;Schwetz et al, 2017). Activation of vitamin D receptor (VDR) localised in osteoblasts, osteocytes, chondrocytes, and osteoclasts regulates cell proliferation, maturation, and mineralization as well as bone resorption.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The relationships of alkaline phosphatase and bone alkaline phosphatase to the growth hormone/insulin-like growth factor-1 axis and vitamin D status in children with growth hormone deficiency

et al. 2018

View full text Add to dashboard Cite

The relationships between bone turnover, the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis and vitamin D are complex, but still not fully explained. The GH/IGF-1 axis and vitamin D can mutually modulate each other's metabolism and influence the activation of cell proliferation, maturation, and mineralization as well as bone resorption. The aim of this study was to evaluate the reciprocal associations between bone formation markers [alkaline phosphatase (ALP), bone alkaline phosphatase (BALP)], the GH/IGF-1 axis and 25-hydroxyvitamin D [25(OH)D] in children with growth hormone deficiency at baseline and during recombinant human growth hormone (rhGH) therapy. ALP, BALP, 25(OH)D and IGF-1 levels were evaluated in 53 patients included in this prospective three-year study. ALP, BALP and IGF-1 increased during rhGH therapy. Baseline ALP activity correlated positively with baseline height velocity (HV). ALP and BALP activity at 12 months correlated positively with HV in the first year of therapy. We found positive correlations between ALP and IGF-1 at baseline and during the first year of therapy, between BALP activity at 12 months and rhGH dose in the first year of therapy, and between doses of cholecalciferol in the first year of rhGH therapy and early changes in BALP activity during rhGH therapy. Our results indicate that vitamin D supplementation enhances the effect of rhGH on bone formation process, which could improve the effects of rhGH therapy. ALP and BALP activity are useful in the early prediction of the effects of rhGH therapy, but their utility as long-term predictors seemed insufficient.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The relationships of alkaline phosphatase and bone alkaline phosphatase to the growth hormone/insulin-like growth factor-1 axis and vitamin D status in children with growth hormone deficiency

et al. 2018

View full text Add to dashboard Cite

show abstract

“…These authors reported significantly higher values in the sunny season (31.1 ± 11.1 ng/mL in June–September) than in the cold season (17.3 ± 5.3 ng/mL in November–February), with 35% having vitamin D insufficiency and 40% vitamin D deficiency. Witkowska-Sedek et al evaluated 84 children and adolescents with GHD and found low 25OHD concentrations (22.3 ± 6.9 ng/mL) [ 32 ], and Savanelli et al evaluated 41 adult GHD patients and found mean 25OHD concentration of 21.3 ± 12.3 ng/mL, with vitamin D deficiency present in 51% of the patients compared to 14.6% of the controls [ 33 ]. In addition, Ameri et al evaluated 69 adult GHD patients, most with postsurgical hypopituitarism [ 34 ], and found that only 6 patients (8.7%) had a serum 25OHD concentration above 30 ng/mL.…”

Section: Discussionmentioning

confidence: 99%

Vitamin D in children with growth hormone deficiency due to pituitary stalk interruption syndrome

2018

View full text Add to dashboard Cite

BackgroundRecent studies have shown a relationship between vitamin D status and growth hormone (GH) and insulin-like growth factor 1 (IGF1). The objective of this study was to assess vitamin D status in children with GH deficiency due to pituitary stalk interruption syndrome (PSIS) and to investigate the relationship between 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25 (OH) 2D) serum levels and patient characteristics.MethodsA retrospective single-center study of 25OHD and 1,25(OH)2D serum concentrations in 50 children with PSIS at the initial evaluation before treatment.ResultsMean concentrations of 33.2 ± 18.0 ng/mL for 25OHD and 74.5 ± 40.7 ng/L for 1,25(OH)2D were measured. Additionally, 25OHD concentrations were significantly higher in boys than in girls (p = 0.04) and lower in the cold season than in the sunny season (p = 0.03). Significant positive correlations were observed between the GH peak and serum 1,25 (OH) 2D concentrations (Rho = 0.35; p = 0.015) and the 1,25(OH)2D/25OHD ratio (Rho = 0.29; p < 0.05). No correlation was found for other characteristics, including IGF1.ConclusionsVitamin D status in children with hypothalamic-pituitary deficiency due to PSIS was similar to that reported in national and European studies in healthy children. The positive significant correlations between the GH peak and the 1,25 (OH)2D concentration as well as with the 1,25 (OH)2D/25OHD ratio suggest that even in these patients who had severely impaired GH secretion and low IGF1 levels, an interplay between the GH/IGF1 axis and the vitamin D system still exists.

show abstract

“…Conversely, reduced 1,25(OH)2-D3 or 25OH-D3 levels in children with GHD have also been demonstrated [29,30]. Ciresi et al found that 40% of Sicilian children with GHD at baseline had vitamin D deficiency and 35% had vitamin D insufficiency, respectively [31].…”

Section: Impact Of Ghd On Vitamin D Levelsmentioning

confidence: 99%

Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess

Ciresi

Giordano

2017

Growth Hormone & IGF Research

View full text Add to dashboard Cite

The interplay between vitamin D and the growth hormone (GH)/insulin-like growth factor (IGF)-I system is very complex and to date it is not fully understood. GH directly regulates renal 1 alpha-hydroxylase activity, although the action of GH in modulating vitamin D metabolism may also be IGF-I mediated. On the other hand, vitamin D increases circulating IGF-I and the vitamin D deficiency should be normalized before measurement of IGF-I concentrations to obtain reliable and unbiased IGF-I values. Indeed, linear growth after treatment of nutritional vitamin D deficiency seems to be mediated through activation of the GH/IGF-I axis and it suggests an important role of vitamin D as a link between the proliferating cartilage cells of the growth plate and GH/IGF-I secretion. Vitamin D levels are commonly lower in patients with GH deficiency (GHD) than in controls, with a variable prevalence of insufficiency or deficiency, and this condition may worsen the already known cardiovascular and metabolic risk of GHD, although this finding is not common to all studies. In addition, data on the impact of GH treatment on vitamin D levels in GHD patients are quite conflicting. Conversely, in active acromegaly, a condition characterized by a chronic GH excess, both increased and decreased vitamin D levels have been highlighted, and the interplay between vitamin D and the GH/IGF-I axis becomes even more complicated when we consider the acromegaly treatment, both medical and surgical. The current review summarizes the available data on vitamin D in the main disorders of the GH/IGF-I axis, providing an overview of the current state of the art.

show abstract

Relationship Between 25(OH)D and IGF-I in Children and Adolescents with Growth Hormone Deficiency

Cited by 22 publications

References 23 publications

The relationships of alkaline phosphatase and bone alkaline phosphatase to the growth hormone/insulin-like growth factor-1 axis and vitamin D status in children with growth hormone deficiency

The relationships of alkaline phosphatase and bone alkaline phosphatase to the growth hormone/insulin-like growth factor-1 axis and vitamin D status in children with growth hormone deficiency

Vitamin D in children with growth hormone deficiency due to pituitary stalk interruption syndrome

Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess

Contact Info

Product

Resources

About